News Lilly takes on Vertex in non-opioid pain with SiteOne buy Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.
News Novo Holdings leads $100m round for novel painkiller biotech SiteOne Therapeutics has completed a $100 million third-round financing that will support clinical trials of its non-opioid painkiller.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.